argenx (NASDAQ:ARGX) Earns Buy Rating from JMP Securities

JMP Securities restated their buy rating on shares of argenx (NASDAQ:ARGXGet Rating) in a research report released on Thursday, Stock Target Advisor reports. JMP Securities currently has a $427.00 price target on the stock.

A number of other brokerages also recently issued reports on ARGX. Piper Sandler lifted their price target on argenx from $450.00 to $465.00 and gave the company an overweight rating in a report on Friday, August 26th. HC Wainwright lifted their price target on argenx from $400.00 to $425.00 and gave the company a buy rating in a report on Friday, July 29th. JPMorgan Chase & Co. lifted their price target on argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the company an overweight rating in a report on Thursday, July 14th. Morgan Stanley lifted their price target on argenx from $375.00 to $401.00 and gave the company an overweight rating in a report on Friday, July 29th. Finally, Stifel Nicolaus lifted their price target on argenx from $460.00 to $471.00 in a report on Thursday, July 28th. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, argenx presently has an average rating of Buy and a consensus target price of $399.65.

argenx Stock Down 1.2 %

ARGX opened at $356.71 on Thursday. The stock’s fifty day moving average is $374.25 and its two-hundred day moving average is $340.23. The company has a market capitalization of $19.64 billion, a P/E ratio of -20.58 and a beta of 0.83. argenx has a 52 week low of $249.50 and a 52 week high of $403.77.

argenx (NASDAQ:ARGXGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported ($3.81) EPS for the quarter, topping the consensus estimate of ($4.76) by $0.95. The company had revenue of $85.18 million for the quarter, compared to the consensus estimate of $40.05 million. argenx had a negative return on equity of 49.45% and a negative net margin of 538.17%. Equities analysts anticipate that argenx will post -15.52 earnings per share for the current year.

Institutional Trading of argenx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in argenx by 3.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,377,316 shares of the company’s stock worth $2,416,237,000 after acquiring an additional 182,835 shares during the period. FMR LLC raised its stake in shares of argenx by 6.3% during the 2nd quarter. FMR LLC now owns 4,974,343 shares of the company’s stock valued at $1,884,680,000 after buying an additional 294,228 shares during the last quarter. Jennison Associates LLC raised its stake in shares of argenx by 51.9% during the 2nd quarter. Jennison Associates LLC now owns 1,545,227 shares of the company’s stock valued at $585,456,000 after buying an additional 527,812 shares during the last quarter. Capital World Investors raised its stake in shares of argenx by 12.0% during the 1st quarter. Capital World Investors now owns 739,392 shares of the company’s stock valued at $233,138,000 after buying an additional 79,119 shares during the last quarter. Finally, Artal Group S.A. raised its stake in shares of argenx by 17.5% during the 1st quarter. Artal Group S.A. now owns 587,500 shares of the company’s stock valued at $185,245,000 after buying an additional 87,500 shares during the last quarter. Institutional investors and hedge funds own 59.75% of the company’s stock.

About argenx

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Recommended Stories

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.